AR064545A1 - Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona - Google Patents
Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanonaInfo
- Publication number
- AR064545A1 AR064545A1 ARP070105913A ARP070105913A AR064545A1 AR 064545 A1 AR064545 A1 AR 064545A1 AR P070105913 A ARP070105913 A AR P070105913A AR P070105913 A ARP070105913 A AR P070105913A AR 064545 A1 AR064545 A1 AR 064545A1
- Authority
- AR
- Argentina
- Prior art keywords
- trifluor
- fluor
- piperazin
- phenyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Los compuestos son para la fabricacion de un medicamento destinado al tratamiento de psicosis, dolor, disfuncion neurodeqenerativa en memoria y aprendizaje, esquizofrenia, demencia y otras enfermedades en las que están desequilibrados los procesos cognitivos, por ejemplo los trastornos con déficit de atencion o la enfermedad de Alzheimer. Reivindicacion 1: Una forma cristalina A de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2- ((S)-2,2,2-trifluor-1-metil- etoxi)-fenil]-metanona, caracterizada por lo menos por tres picos elegidos entre los siguiente picos de difraccion de rayos X obtenidos con radiacion Cukalfa, expresado en grados 2-theta = 13,1, 14,3, 15,4, 16,2, 17,1, 17,2, 17,6, 18,0, 19,8, 20,1, 20,4, 21,0, 22,6 y 24,3 (+- 0,2).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06127269 | 2006-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064545A1 true AR064545A1 (es) | 2009-04-08 |
Family
ID=38988312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105913A AR064545A1 (es) | 2006-12-28 | 2007-12-27 | Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona |
Country Status (33)
Country | Link |
---|---|
US (5) | US20080214561A1 (es) |
EP (1) | EP2114405B1 (es) |
JP (1) | JP4799666B2 (es) |
KR (1) | KR101130146B1 (es) |
CN (1) | CN101573114A (es) |
AR (1) | AR064545A1 (es) |
AU (1) | AU2007341356B2 (es) |
BR (1) | BRPI0720829B8 (es) |
CA (1) | CA2673667A1 (es) |
CL (1) | CL2007003830A1 (es) |
CO (1) | CO6190613A2 (es) |
CR (1) | CR10846A (es) |
CY (1) | CY1116350T1 (es) |
DK (1) | DK2114405T3 (es) |
EC (1) | ECSP099471A (es) |
ES (1) | ES2535040T3 (es) |
HR (1) | HRP20150573T1 (es) |
HU (1) | HUE025032T2 (es) |
MA (1) | MA31029B1 (es) |
MX (1) | MX2009006859A (es) |
MY (1) | MY188367A (es) |
NO (1) | NO342150B1 (es) |
NZ (1) | NZ577502A (es) |
PE (1) | PE20081556A1 (es) |
PL (1) | PL2114405T3 (es) |
PT (1) | PT2114405E (es) |
RS (1) | RS53910B1 (es) |
RU (1) | RU2463295C2 (es) |
SI (1) | SI2114405T1 (es) |
TW (1) | TWI388552B (es) |
UA (1) | UA100232C2 (es) |
WO (1) | WO2008080821A1 (es) |
ZA (1) | ZA200904423B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2114405E (pt) | 2006-12-28 | 2015-06-02 | Hoffmann La Roche | Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona |
US8586587B2 (en) | 2009-02-26 | 2013-11-19 | Thar Pharmaceuticals, Inc. | Crystalline molecular complex of tadalafil and methylparaben |
KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
CN104334550A (zh) * | 2012-05-25 | 2015-02-04 | 巴斯夫欧洲公司 | 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B |
US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
CN116212025A (zh) | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
WO2022251458A1 (en) * | 2021-05-27 | 2022-12-01 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
SI1656361T1 (sl) * | 2003-08-11 | 2008-04-30 | Hoffmann La Roche | Piperazin z OR-substituirano fenilno skupino in njuna uporaba kot zaviralca GLYT1 |
PT2114405E (pt) | 2006-12-28 | 2015-06-02 | Hoffmann La Roche | Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona |
-
2007
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en active Application Filing
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active IP Right Grant
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 RS RS20150229A patent/RS53910B1/en unknown
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
- 2015-05-28 HR HRP20150573TT patent/HRP20150573T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064545A1 (es) | Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona | |
WO2008099210A3 (en) | Piperazine derivatives for treatment of ad and related conditions | |
BRPI0414209A (pt) | derivados de 1-(2-amino-benzol)-piperazina como inibidores de captação de glicina para o tratamento de psicoses | |
TW200734311A (en) | New compounds | |
TNSN06042A1 (en) | Piperazine with or-substituted phenyl group and their use as glyt 1 inhibitors | |
WO2007058583A3 (en) | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | |
CY1117663T1 (el) | Παραγωγα 6,7-διυδρο-πυραζολο[1,5-α]πυραζιν-4-υλαμινης χρησιμα ως αναστολεις β-σεκρετασης (bace) | |
EA201100794A1 (ru) | Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак | |
EA200901373A1 (ru) | Аминогетероциклические соединения | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ZA200608628B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
TW201144302A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | |
NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
WO2008076046A8 (en) | Novel 2-amino-5, 5-diaryl-imidazol-4-ones | |
EA201101330A1 (ru) | Замещенные пиримидины, предназначенные для лечения рака | |
EA201100255A1 (ru) | 5-алкинилпиримидины | |
EA200702004A1 (ru) | Соль безилата 7-(2-(4-(3-трифторметилфенил)-1,2,3,6-тетрагидропирид-1-ил)этил)изохинолина, ее получение и применение в терапии | |
ATE502026T1 (de) | Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung | |
DE602004031744D1 (de) | Kristallisation von festen formen von clopidogreladditionssalzen | |
NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
TW200700390A (en) | Metabolites for nk-1 antagonists for emesis | |
WO2008030391A3 (en) | Difluorinated piperidines for treatment of alzheimer's disease and related conditions | |
WO2007033774A3 (de) | Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung | |
DE602004026597D1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |